OUR PROGRAMS OUR SCIENCE RESOURCE LINKS NEWS ABOUT US  
 
  
  What are ADDLs?
Why are they relevant?
How can they be treated?
Intellectual Property

Acumen
Publications
Other Publications
Acumen Presentations

Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins
M. P. Lambert, A. K. Barlow, B. A. Chromy, E. Edwards, R. Freed, M Liosatos, T. E. Morgan, I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft, and W. L. Klein
Proceedings of the National Academy of Science USA (1998) Vol. 95, 6448–6453

ABSTRACT:  Aβ1–42 is a self-associating peptide whose neurotoxic derivatives are thought to play a role in Alzheimer’s pathogenesis. Neurotoxicity of amyloid b protein (Aβ) has been attributed to its fibrillar forms, but experiments presented here characterize neurotoxins that assemble when fibril formation is inhibited. These neurotoxins comprise small diffusible Aβ oligomers (referred to as ADDLs, for Aβ-derived diffusible ligands), which were found to kill mature neurons in organotypic central nervous system cultures at nanomolar concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-derived tryptic peptides blocked binding and afforded neuroprotection. Germ-line knockout of Fyn, a protein tyrosine kinase linked to apoptosis and elevated in Alzheimer’s disease, also was neuroprotective.  Remarkably, neurological dysfunction evoked by ADDLs occurred well in advance of cellular degeneration. Without lag, and despite retention of evoked action potentials, ADDLs inhibited hippocampal long-term potentiation, indicating an immediate impact on signal transduction. We hypothesize that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer’s disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Aβ-derived diffusible ligands acting upon particular neural signal transduction pathways.

 

Home | Contact Us | Our Programs | Our Science | News | Site Map
Copyright © 2006 Acumen Pharmaceuticals, Inc.